Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I/II Clinical Trial With Randomized, Blinded, Controlled Design to Evaluate the Safety and Immunogenicity of the Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Populations Aged 40 Years and Older Post -Vaccination

Authors not listed

Ab&B Bio-tech Co., Ltd.JS · 2025

Abstract

The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2025). A Phase I/II Clinical Trial With Randomized, Blinded, Controlled Design to Evaluate the Safety and Immunogenicity of the Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Populations Aged 40 Years and Older Post -Vaccination. <em>Ab&B Bio-tech Co., Ltd.JS</em>. https://clinicaltrials.gov/study/NCT06851832
Vancouver
Anonymous. A Phase I/II Clinical Trial With Randomized, Blinded, Controlled Design to Evaluate the Safety and Immunogenicity of the Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Populations Aged 40 Years and Older Post -Vaccination. Ab&B Bio-tech Co., Ltd.JS. 2025.
BibTeX
@misc{anon2025APhase, title = {A Phase I/II Clinical Trial With Randomized, Blinded, Controlled Design to Evaluate the Safety and Immunogenicity of the Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Populations Aged 40 Years and Older Post -Vaccination}, author = {Anonymous}, journal = {Ab&B Bio-tech Co., Ltd.JS}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings